Treatment for Very Low Favorable Histology Wilms Tumor

Gender PreferenceNone
Age Group0 - 99 years
Research Start DateFebruary 18, 2009
Research End DateFebruary 18, 2019
Principal InvestigatorAyman El-Sheikh, MD
Description

Participants in this research study have a favorable histology Wilms tumor that has some risk of returning after treatment. The purpose of this research study is to find out if subjects with a higher risk of having their tumor return will benefit from the addition of doxorubicin or the current standard treatment. Approximately 5 people will take part in this study at the University of Iowa. Study involvement will last for 25 weeks and will have follow-up examinations and tests for about 5 years.

Contact Info

Julie de la Garza, 319-356-3749

Keywordsspan itemProp='description'>AREN0532 ; cancer ; doxorubicin ; el-sheikh ; IRB#200812777 ; pediatric ; phase 3 ; phase III ; Wilms tumor ;